Has the Canadian Life Sciences Industry valuation changed over the past few years?

There are only 2 companies in the Canadian Life Sciences industry, so there is insufficient data to make an industry-wide assessment of both the PE and PS ratio.

Which industries have driven the changes within the Canadian Healthcare industry?

There are no additional sub-industries under this industry.

Canadian (TSX) Life Sciences Industry Analysis

Date	Market Cap	Revenue	Earnings	PE	Absolute PE	PS
Sun, 31 May 2026	CA$58.0m	CA$11.1m	-CA$3,557,105.00	n/a	-16.3x	5.2x
Tue, 28 Apr 2026	CA$48.3m	CA$11.6m	-CA$3,092,264.00	115.4x	-15.6x	4.1x
Thu, 26 Mar 2026	CA$36.6m	CA$10.7m	-CA$2,051,096.00	23.1x	-17.8x	3.4x
Sat, 21 Feb 2026	CA$85.2m	CA$10.7m	-CA$5,159,522.00	31.2x	-16.5x	7.9x
Mon, 19 Jan 2026	CA$105.1m	CA$9.2m	-CA$4,287,830.00	35.3x	-24.5x	11.4x
Wed, 17 Dec 2025	CA$97.1m	CA$9.1m	-CA$5,080,530.00	36.6x	-19.1x	10.7x
Fri, 14 Nov 2025	CA$104.4m	CA$8.2m	-CA$5,196,461.00	44.9x	-20.1x	12.7x
Sun, 12 Oct 2025	CA$111.2m	CA$8.2m	-CA$5,196,461.00	36.5x	-21.4x	13.5x
Tue, 09 Sep 2025	CA$98.9m	CA$8.2m	-CA$5,027,198.00	39.3x	-19.7x	12x
Thu, 07 Aug 2025	CA$88.5m	CA$7.7m	-CA$4,902,516.00	31.1x	-18.1x	11.6x
Sat, 05 Jul 2025	CA$90.6m	CA$7.5m	-CA$4,601,329.00	37.5x	-19.7x	12.1x
Mon, 02 Jun 2025	CA$70.0m	CA$7.5m	-CA$4,525,404.00	30.4x	-15.5x	9.3x
Wed, 30 Apr 2025	CA$53.6m	CA$6.6m	-CA$4,692,828.00	32.1x	-11.4x	8.1x
Fri, 28 Mar 2025	CA$58.3m	CA$5.6m	-CA$4,854,396.00	n/a	-12x	10.4x
Sun, 23 Feb 2025	CA$26.9m	CA$5.6m	-CA$2,150,439.00	n/a	-12.5x	4.8x
Tue, 21 Jan 2025	CA$30.4m	CA$5.9m	-CA$1,591,902.00	n/a	-19.1x	5.1x
Thu, 19 Dec 2024	CA$26.4m	CA$5.4m	-CA$1,321,782.00	n/a	-20x	4.9x
Sat, 16 Nov 2024	CA$25.9m	CA$5.1m	-CA$1,418,028.00	n/a	-18.2x	5x
Mon, 14 Oct 2024	CA$28.3m	CA$5.1m	-CA$1,418,028.00	n/a	-20x	5.5x
Wed, 11 Sep 2024	CA$57.1m	CA$5.1m	-CA$4,554,454.00	n/a	-12.5x	11.1x
Fri, 09 Aug 2024	CA$58.2m	CA$5.1m	-CA$4,366,737.00	n/a	-13.3x	11.3x
Sun, 07 Jul 2024	CA$58.7m	CA$4.9m	-CA$4,098,591.00	n/a	-14.3x	11.9x
Tue, 04 Jun 2024	CA$63.0m	CA$4.9m	-CA$3,824,483.00	n/a	-16.5x	12.8x
Thu, 02 May 2024	CA$58.1m	CA$4.9m	-CA$3,805,287.00	n/a	-15.3x	11.9x
Sat, 30 Mar 2024	CA$68.0m	CA$4.9m	-CA$2,943,594.00	n/a	-23.1x	13.8x
Mon, 26 Feb 2024	CA$53.5m	CA$4.9m	-CA$1,290,813.00	n/a	-41.4x	10.9x
Wed, 24 Jan 2024	CA$209.5m	CA$23.4m	-CA$24,636,048.00	n/a	-8.5x	9x
Fri, 22 Dec 2023	CA$199.0m	CA$23.5m	-CA$24,854,730.00	n/a	-8x	8.5x
Sun, 19 Nov 2023	CA$197.8m	CA$23.7m	-CA$24,695,492.00	n/a	-8x	8.4x
Tue, 17 Oct 2023	CA$195.8m	CA$23.7m	-CA$24,695,492.00	n/a	-7.9x	8.3x
Thu, 14 Sep 2023	CA$196.4m	CA$23.7m	-CA$24,644,997.00	n/a	-8x	8.3x
Sat, 12 Aug 2023	CA$197.4m	CA$23.5m	-CA$24,780,404.00	n/a	-8x	8.4x
Mon, 10 Jul 2023	CA$197.6m	CA$23.5m	-CA$24,780,404.00	n/a	-8x	8.4x
Wed, 07 Jun 2023	CA$174.0m	CA$22.5m	-CA$25,042,100.00	n/a	-6.9x	7.7x


CA Market	0.44%
Healthcare	2.42%
Life Sciences	-16.65%
Clinical Research and Equipment	-16.65%

	Company	Last Price	7D	1Y	Valuation
No data available

Announcement • May 07

Sona Nanotech Inc Announces Clinical Strategy with Two THT Combination Therapy Studies in Melanoma

Sona Nanotech Inc. announced its clinical strategy to further the development of its Targeted Hyperthermia Therapy ("THT") cancer treatment. Based on both the success of Sona's first-in-human clinical study with THT, which demonstrated its ability to shrink and prime tumors immunogenically when used alone, and the published results from preclinical testing of Sona's THT showing the higher and more durable response rates that were observed when THT is combined with standard immunotherapies, the Company now intends to trial advanced applications of THT in two innovative clinical studies in melanoma patients combining THT with immunotherapy drugs. Sona will undertake its next clinical study of THT, (the "IGNITE-THT Study" - Immunotherapy + THT to Generate Novel Immune Tumor Eradication). In this study, Sona's THT would be administered in conjunction with a regimen of intratumoral and systemic dosing of the same immunotherapy drugs on which a cohort of patients had previously failed. The IGNITE-THT Study is expected to demonstrate the same safety and tolerability as experienced in the Company's previous clinical study, but with enhanced efficacy and long-term durability from the combination therapy anticipated after tumors are immunogenically activated by Sona's THT treatment. A second study, (the "PRIME-THT Study" - Precision Regional Immunotherapy for Melanoma Enhanced by THT) will assess the same concept but in newly diagnosed early-stage melanoma sufferers, which represents a much larger number of affected people worldwide (estimated by management to be up to 275,000 globally each year). Patients in this study would be given THT in combination with intratumoral immunotherapy with a view to stopping tumors from spreading (metastasising) by THT activating strong immune responses prior to standard-of-care surgical tumor resection. In addition to evaluating the safety and tolerability of Sona's THT treatment in an 'up-front' (neo-adjuvant) setting, the PRIME-THT Study will also measure the immediate treatment effect and the long-term durability of responses related to this novel, early-stage, neo-adjuvant combination therapy. These new studies are designed to answer the same questions from different ends of the patient journey: can THT convert immunogenically 'cold' tumors into tumors that respond to immunotherapies? The IGNITE-THT Study will ask it for patients who have already failed on treatment and remain on immunotherapy's treatment plateau. The PRIME-THT Study asks it earlier, enabling and bringing the benefits of immunotherapy forward into the pre-resection window, where stopping metastases is still possible. Early result read-outs from the IGNITE-THT and PRIME-THT studies are expected within six and eight months of their initiation, respectively. An expansion to a second cancer indication. Demonstrating THT in both early and late-stage melanoma indications shows a greater breadth of potential treatment market size. Two near-term valuation catalysts. A clear strategy to demonstrate long-term potential to the investment community with relatively near-term deliverables. Potential for greater chances of cure. Priming tumors with THT to engage the immune system prior to the administration of today's best immunotherapy drugs could result in higher response rates to those drugs. Potential for reduced risk of metastases. Pre-treating early-stage melanoma tumors could reduce the chances that the cancer spreads to lymph nodes prior to standard-of-care resection. The Company also continues to lay the groundwork for a larger scale, clinical trial in Canada for late-stage melanoma patients, working with Health Canada to secure the required investigational testing authorization ("ITA"). Feedback received from Health Canada is guiding the Company's ITA application for a combination strategy clinical trial which it expects to begin early in 2027 and run for up to 18 months with multiple read-out milestones.

Canadian (TSX) Life Sciences Industry Analysis

Industry Valuation and Performance

Industry Trends

Top Stock Gainers and Losers

Latest News

First quarter 2026 earnings released

Sona Nanotech Inc Announces Clinical Strategy with Two THT Combination Therapy Studies in Melanoma

New major risk - Financial position